|
|
|
Volumn 7, Issue 6, 2007, Pages 449-450
|
|
Second interim efficacy analysis of the BCIRG 006 trial: Adjuvant chemotherapy with or without trastuzumab in HER2-overexpressing breast cancer
a a a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CARBOPLATIN;
CYCLOPHOSPHAMIDE;
DNA TOPOISOMERASE (ATP HYDROLYSING);
DOCETAXEL;
DOXORUBICIN;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
TRASTUZUMAB;
ADJUVANT THERAPY;
ANEMIA;
ARTHRALGIA;
BREAST CANCER;
CANCER INVASION;
CLINICAL TRIAL;
COMBINATION CHEMOTHERAPY;
CONFERENCE PAPER;
CONGESTIVE HEART FAILURE;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE FREE SURVIVAL;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TOLERABILITY;
FLUORESCENCE IN SITU HYBRIDIZATION;
FOLLOW UP;
GENE AMPLIFICATION;
GENE DELETION;
HAND FOOT SYNDROME;
HEART LEFT VENTRICLE EJECTION FRACTION;
HUMAN;
LEUKOPENIA;
LYMPH NODE METASTASIS;
MAJOR CLINICAL STUDY;
MONOTHERAPY;
MOTOR NEUROPATHY;
MULTIPLE CYCLE TREATMENT;
MYALGIA;
NAIL;
NEUTROPENIA;
OVERALL SURVIVAL;
PROTEIN EXPRESSION;
RANDOMIZED CONTROLLED TRIAL;
SENSORY NEUROPATHY;
SIDE EFFECT;
STOMATITIS;
THROMBOCYTOPENIA;
VOMITING;
|
|
EID: 33947261105
PISSN: 15268209
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (2)
|
|
References (0)
|